Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.

Area of Science:

• Biochemistry and Molecular Biology
• Epidemiology
• Nutritional Science

Background:

• Enterolactone is a phytoestrogen derived from plant lignans by gut microflora.
• Phytoestrogens, including enterolactone, have been investigated for potential cancer-protective properties.
• The specific role of enterolactone in prostate cancer risk remains unclear.

Purpose of the Study:

• To investigate the association between circulating enterolactone concentrations and the risk of subsequent prostate cancer diagnosis.
• To evaluate whether enterolactone acts as a protective factor against prostate cancer development.
• To analyze this relationship across large, well-characterized Nordic cohorts.

Main Methods:

• A longitudinal, nested case-control study design was employed.
• Data were linked from three Nordic biobanks (Finland, Norway, Sweden) to cancer registries.
• Serum enterolactone levels were measured using time-resolved fluoroimmunoassay in 794 prostate cancer cases and 2,550 matched controls.

Main Results:

• Median enterolactone concentrations were similar between prostate cancer cases and control subjects (8.4 nmol/L vs. 8.5 nmol/L).
• Odds ratios for prostate cancer risk did not significantly increase with higher quartiles of enterolactone.
• Analysis within individual national cohorts also failed to demonstrate a protective effect.

Conclusions:

• The study provides no support for the hypothesis that high circulating enterolactone levels are protective against prostate cancer.
• Dietary lignan intake, as reflected by enterolactone levels, may not significantly influence prostate cancer risk in this population.
• Further research may be needed to explore other dietary factors or mechanisms in prostate cancer prevention.